PUMA
Istituto di Fisiologia Clinica     
Burney P., Soriano J. B., Vollmer W. M., Viegi G., Sullivan S. D., Fabbri L. M., Sin D. D., Coutas E. P., Bourberau J., Mapel D. W., Weiss K., McLaughlin T., Price D., Strkenboom M. C., Taylor R., Hagam G. W. The pharmacoepidemiology of COPD: recent advances and methodological discussion. In: European Respiratory Journal, vol. 22 pp. 1s - 4s. The European Respiratory Society, 2003.
 
 
Abstract
(English)
Chronic obstructive pulmonary disease (COPD) threatens an emerging public health crisis. The two major drivers for this are the ageing of the world's population and the impressive, if deplorable, success of the multinational tobacco companies at forcing open world markets. Although the World Health Organization estimates that COPD is the sixth most common cause of death worldwide and that by 2020 it will be the third most common, COPD is also an orphan condition that overwhelmingly affects the poor and has been broadly ignored by scientists and by governments. Although the cost-effectiveness of smoking cessation, pulmonary rehabilitation, and long-term oxygen therapy in the later stages of the disease are all high, there is little active treatment that can currently be offered.
URL: http://erj.ersjournals.com/cgi/reprint/22/43_suppl/1S?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&volume=43&firstpage=1&resourcetype=HWCIT
Subject pharmacoepidemiology
methodological
COPD


Icona documento 1) Download Document PDF


Icona documento Open access Icona documento Restricted Icona documento Private

 


Per ulteriori informazioni, contattare: Librarian http://puma.isti.cnr.it

Valid HTML 4.0 Transitional